N/A
Completed N=110
A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Source: ClinicalTrials.gov NCT00408200 ↗Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Mar 2013
Primary outcomePrimary: Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug — 24; 10 participants
Summary
The purpose of this study is to examine the overall effectiveness of anti-arrhythmic medicines (to control heart rhythm) prescribed after an ablation procedure for atrial fibrillation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Composite Endpoint: Atrial Arrhythmias Lasting >24 Hrs or Requiring Antiarrhythmic Drug Therapy; Need for Cardioversion/Repeat Ablation During the Study Period; Adverse Outcome/Intolerance of Antiarrhythmic Agent Requiring Cessation or Change of Drug |
24; 10 | — |
| SECONDARY Freedom From Atrial Arrhythmia at 6 Months Post Procedure. |
39; 35 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- Adult patients meeting ACC/AHA criteria for paroxysmal atrial fibrillation (episodes typically last no more than 7 days and are self-terminating)
- Eligible for pulmonary vein isolation
- Able to tolerate antiarrhythmic medication
Exclusion Criteria
- Age 7 days and require cardioversion)
- Antiarrhythmic treatment for indication other than atrial fibrillation
- Contraindication or intolerance to all antiarrhythmic medications
- Primary physician unwilling to withhold antiarrhythmic drugs for duration of the study
- Failure to obtain informed consent
Data sourced from ClinicalTrials.gov (NCT00408200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.